Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
Abstract Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenit...
Enregistré dans:
Auteurs principaux: | Anick Bérard, Shannon Strom, Jin-Ping Zhao, Shashi Kori, Detlef Albrecht |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8872f81c01f84aba9c5de34e563332be |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Prevalence and duration of prescribed opioid use during pregnancy: a cohort study from the Quebec Pregnancy Cohort
par: Jin-Ping Zhao, et autres
Publié: (2021) -
Associations of early pregnancy BMI with adverse pregnancy outcomes and infant neurocognitive development
par: Yu-Ting Chen, et autres
Publié: (2021) -
Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
par: Fatima Tauqeer, et autres
Publié: (2021) -
Association of maternal pre-pregnancy low or increased body mass index with adverse pregnancy outcomes
par: Jie Tang, et autres
Publié: (2021) -
Asthma during pregnancy in a population-based study--pregnancy complications and adverse perinatal outcomes.
par: Gustaf Rejnö, et autres
Publié: (2014)